Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the mainstay treatments for SLE. Unfortunately, many patients with SLE fail to respond to these therapies and/or experience significant adverse events. In these patients, clinicians may utilize other available agents, such as the biologics Benlysta (GSK) and Rituxan (Roche; off-label). This content provides manufacturers of current treatments and developers of novel SLE agents with insights into the use of SLE drugs and into the market trends in the SLE space.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed SLE patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed SLE patients?
- How has Benlysta been integrated into the treatment algorithm, and what is its source of business?
- What percentage of SLE patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of SLE patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: GlaxoSmithKline, Roche, Bristol Myers Squibb
Key drugs: Benlysta, Rituxan, mycophenolate mofetil, azathioprine, cyclosporine, cyclophosphamide, hydroxychloroquine, leflunomide, methotrexate, tacrolimus, mycophenolate sodium, Orencia
- Systemic Lupus Erythematosus - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) 2021
- Treatment Algorithm Claims Data Analysis PPT | Systemic Lupus Erythematosus | US | January 2021
- Treatment Algorithms: Claims Data Analysis Systemic Lupus Erythematosus US 2021 Dashboard
Ajay Puri, M.B.A.
Ajay Puri, M.B.A., is an analyst on the Immune and Inflammatory Disorders team at Clarivate. He has developed expertise in ulcerative colitis, Crohn’s disease, and systemic lupus erythematosus. Previously, he worked as a knowledge management associate at ZS Associates, where he conducted competitive assessment, company and product profiling, and other projects. He holds a bachelor’s degree in pharmacy and an M.B.A. in marketing from the National Institute of Pharmaceutical Education and Research in Mohali, India.